-
摘要: 心力衰竭(心衰)作为一种严重的心脏疾病，其发病率和病死率随着人口老龄化的增加而上升。药物治疗仍是核心，一些新药已显示出优秀的治疗效果。推陈出新的器械治疗也展示出有益的效果。未来的研究成果有望进一步改善患者的预后。Abstract: Heart failure(HF) is a serious heart disease. Its incidence rate and mortality increase with the aging of the population. Drug therapy remains the core role, and some new drugs have shown excellent therapeutic effects. Instrument therapy has also shown beneficial effects. Future research will aim to improve the HF prognosis.
-
Key words:
- heart failure /
- treatment
-
-
[1] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368
[2] Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023, 118(17): 3272-3287. doi: 10.1093/cvr/cvac013
[3] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303
[4] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424. doi: 10.1056/NEJMoa2022190
[5] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461. doi: 10.1056/NEJMoa2107038
[6] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. doi: 10.1056/NEJMoa2206286
[7] McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639. doi: 10.1093/eurheartj/ehad195
[8] Gonzalez-Juanatey JR, Gorriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: protecting kidney and heart[J]. Ann Med, 2023, 55(1): 502-513. doi: 10.1080/07853890.2023.2171110
[9] Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic(CKM)syndrome: a scientific statement from the american heart association[J]. Circulation, 2023, 148(20): 1636-1664. doi: 10.1161/CIR.0000000000001186
[10] Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020, 383(23): 2219-2229. doi: 10.1056/NEJMoa2025845
[11] Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med, 2021, 385(24): 2252-2263. doi: 10.1056/NEJMoa2110956
[12] Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action[J]Nat Rev Cardiol, 2023, 20(7): 463-474. doi: 10.1038/s41569-023-00849-3
[13] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med, 2023, 389(24): 2221-2232. doi: 10.1056/NEJMoa2307563
[14] Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2023, 389(12): 1069-1084. doi: 10.1056/NEJMoa2306963
[15] Bagno L, Hatzistergos KE, Balkan W, et al. Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges[J]. Mol Ther, 2018, 26(7): 1610-1623. doi: 10.1016/j.ymthe.2018.05.009
[16] Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cell therapy: a promising cell-based therapy for treatment of myocardial infarction[J]. J Gene Med, 2017, 19(12): 110.
[17] Perin EC, Borow KM, Henry TD, et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure[J]. J Am Coll Cardiol, 2023, 81(9): 849-863. doi: 10.1016/j.jacc.2022.11.061
[18] 中华医学会组织修复与再生分会心脏再生学组. 自体干细胞移植治疗心力衰竭中国专家共识(2022)[J]. 中华医学杂志, 2023, 103(18): 1376-1385.
[19] Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure(STRONG-HF): a multinational, open-label, randomised, trial[J]. Lancet, 2022, 400(10367): 1938-1952. doi: 10.1016/S0140-6736(22)02076-1
[20] Messika-Zeitoun D, Verta P, Gregson J, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis[J]. Eur J Heart Fail, 2020, 22(10): 1803-1813. doi: 10.1002/ejhf.1830
[21] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7): 561-632.
[22] Misumida N, Steidley DE, Eleid MF. Edge-to-edge tricuspid valve repair for severe tricuspid regurgitation 20 years after cardiac transplantation[J]. ESC Heart Fail, 2020, 7(6): 4320-4325. doi: 10.1002/ehf2.12992
[23] Rehan ST, Eqbal F, Ul Hussain H, et al. Transcatheter Edge-to-Edge repair for tricuspid regurgitation-a systematic review and meta-analysis[J]. Curr Probl Cardiol, 2024, 49(1 Pt B): 102055.
[24] Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation[J]. N Engl J Med, 2023, 388(20): 1833-1842. doi: 10.1056/NEJMoa2300525
-
计量
- 文章访问数: 608
- PDF下载数: 103
- 施引文献: 0
下载: